Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion via NF-κB inhibition

Kai Li,Zhicheng Zhang,Yu Mei,Qingzhu Yang,Shupei Qiao,Cheng Ni,Yao Yao,Xinyuan Li,Mengmeng Li,Dongdong Wei,Wangjun Fu,Xuefei Guo,Xuemei Huang,Huanjie Yang
DOI: https://doi.org/10.7150/thno.51976
IF: 11.6
2021-01-01
Theranostics
Abstract:<p>Resistance to chemotherapy is a long-standing problem in the management of cancer, and cancer stem cells are regarded as the main source of this resistance. This study aimed to investigate metallothionein (MT)-1G involvement in the regulation of cancer stemness and provide a strategy to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC).</p><p><b>Methods:</b> MT1G was identified as a critical factor related with gemcitabine resistance in PDAC cells by mRNA microarray. Its effects on PDAC stemness were evaluated through sphere formation and tumorigenicity. LC-MS/MS analysis of conditional medium revealed that activin A, a NF-κB target, was a major protein secreted from gemcitabine resistant PDAC cells. Both loss-of-function and gain-of-function approaches were used to validate that MT1G inhibited NF-κB-activin A pathway. Orthotopic pancreatic tumor model was employed to explore the effects on gemcitabine resistance with recombinant follistatin to block activin A.</p><p><b>Results:</b> Downregulation of <i>MT1G</i> due to hypermethylation of its promoter is related with pancreatic cancer stemness. Secretome analysis revealed that activin A, a NF-κB target, was highly secreted by drug resistant cells. It promotes pancreatic cancer stemness in Smad4-dependent or independent manners. Mechanistically, MT1G negatively regulates NF-κB signaling and promotes the degradation of NF-κB p65 subunit by enhancing the expression of E3 ligase TRAF7. Blockade of activin A signaling with follistatin could overcome gemcitabine resistance.</p><p><b>Conclusions:</b> MT1G suppresses PDAC stemness by limiting activin A secretion <i>via</i> NF-κB inhibition. The blockade of the activin A signaling with follistatin may provide a promising therapeutic strategy for overcoming gemcitabine resistance in PDAC.</p>
medicine, research & experimental
What problem does this paper attempt to address?